A Bayesian adaptive design for two-stage clinical trials with survival data.

Department of Statistics, University of Calcutta, 35 Ballygunge Circular Road, Kolkata 700 019, India.
Lifetime Data Analysis (Impact Factor: 0.54). 11/2009; 15(4):468-92. DOI: 10.1007/s10985-009-9134-4
Source: PubMed

ABSTRACT A randomized two-stage adaptive Bayesian design is proposed and studied for allocation and comparison in a phase III clinical trial with survival time as treatment response. Several exact and limiting properties of the design and the follow-up inference are studied, both numerically and theoretically, and are compared with a single-stage randomized procedure. The applicability of the proposed methodology is illustrated by using some real data.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Adaptive sample size methods have been a popular topic in the field of clinical trials. There are a few basic requirements for the adaptive methods to be acceptable from the international regulatory viewpoint. All valid methods need to control the overall type-I error rate at the pre-specified level. The rule of the interim and final decisions needs to be explicit and clearly documentable. It is extremely desirable that the method employed also provides estimation of the treatment effect in addition to the significance test. In this paper we describe the point and confidence interval estimation for the likelihood approach of sample-size adaptive design proposed by Li et al. (Biostatistics 3:277–287, 2002, J. Biopharm. Stat. 15:707–718, 2005). We use the median unbiased estimator (Cox and Hinkley, Theoretical Statistics, p.273, 1974) for estimating the treatment effect and demonstrate that the estimator has small mean squared error compared to the naïve method, and that the confidence interval estimation has correct coverage probability. KeywordsAdaptive design-Confidence interval-Interim analysis-Sample size re-estimation
    Statistics in Biosciences 01/2010; 2(2):180-190.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, investigators have increasingly recognized the inadequacy of the current phase I, II, and III clinical trial framework. As a response, new designs using innovative statistical techniques have been developed to add increased flexibility to the drug development process. The primary focus of this chapter is to provide an overview of increasingly popular adaptive clinical trial designs and outline the advantages and limitations of such methods. In this chapter, we review advantages of adaptive designs over more traditional group sequential designs. Major topics to be covered include adaptive methods for dose finding in oncology, outcome adaptive clinical trial designs, randomized discontinuation designs, advances in the statistics of personalized medicine, the role of Bayesian methods within the adaptive design arena, and sample size re-estimation methods. KeywordsAdaptive designs-Innovative clinical trial designs
    03/2010: pages 467-481;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the present work, we find a set of reliability functionals to fix up an allocation strategy among K(≥2) treatments when the response distributions, conditionally dependent on some continuous prognostic variable, are exponential with unknown linear regression functions as the means of the respective conditional distributions. Targeting such reliability functionals, we propose a covariate-adjusted response-adaptive randomization procedure for the multi-treatment single-period clinical trial under the Koziol–Green model for informative censoring. We compare the proposed procedure with its competitive covariate-eliminated procedure.
    Statistics: A Journal of Theoretical and Applied Statistics 01/2012; · 1.59 Impact Factor